برجاء الإنتظار ...

Search Results



نشرة الممارس الصحي نشرة معلومات المريض بالعربية نشرة معلومات المريض بالانجليزية صور الدواء بيانات الدواء
 لم يتم إدخال بيانات نشرة معلومات المريض لهذا الدواء حتى الآن
 لم يتم إدخال بيانات نشرة معلومات المريض لهذا الدواء حتى الآن
 Read this leaflet carefully before you start using this product as it contains important information for you

Alka-Ur

Each sachet contains Sodium Bicarbonate 1.76gm, Tartaric acid 0.890, Citric Acid anhydrous 0.720 gm, Tri sodium citrate anhydrous 0.630 gm

Effervescent Granules White to off white crystalline powder gives effervescence on addition of water

Urinary Alkalinizer
Relief from the burning pain of cystitis


Adult Dose- Add the contents of 1 to 2 sachets to a glass of cool water and mix. Alka-ur may be taken up to four times daily. Do not take for more than five days
unless advised to do so by your doctor.
Children under 12 years old- Do not give Alka-Ur unless advised to do so by a doctor.


Route of Administration: Oral


Renal failure or hypernatraemia in conjunction with hexamine mandelate or hexamine hippurate therapy because an acid urine is needed. Caution is advised in overt and occult cardiac failure. Concomitant use of urinary alkalinisers and quinolone antibiotics should be avoided; crystalluria may be more likely to occur with alkaline urine.

Patients should be advised to consult a doctor if pain or irritation persists for more than 48 hours or if blood is noticed in their urine.

This preparation contains 650 mg of sodium per sachet, which should be taken into account by those on a low sodium diet.

Alka-Ur should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary oedema and pre-eclampsia.

The clinical condition of the patient should be evaluated and laboratory determinations (eg. serum electrolytes, acid-base balance) obtained periodically during Alka-ur therapy, particularly in patients with renal disease.


General: Alkalisation of the urine due to the use of Alka-Ur, theoretically, may result in a decreased therapeutic effect of the following medications: chlorpropamide, lithium, salicylates and tetracyclines.

Alternatively, alkalisation of the urine due to the use of Alka-ur, theoretically, may result in an increased therapeutic effect of the following medications: amphetamines,ephedrine/pseudoephedrine

Antacids: Concomitant use of antacids with citrates may result in systemic alkalosis.

Concomitant administration of antacids with sodium citrate and sodium bicarbonate may promote the development of calcium stones in patients with uric acid stones and may also cause hypematremia.

Concurrent use of aluminium-containing antacids with citrate salts can increase aluminium absorption, possibly resulting in acute aluminium toxicity, especially in patients with renal insufficiency.

Quinolones: Citrates may reduce the solubility of ciprofloxacin, norfloxacin or ofloxacin in the urine. Patients should be observed for signs of crystalluria and nephrotoxicity.

Laxatives: Concurrent administration of citrates with laxatives may have an additive effect


Pregnancy
Studies regarding the effect of citrates on pregnancy have not been done.
Lactation
Caution should be exercised when administered to a breast-feeding mother.


Not available


The tartrate component of Alka-ur may be incompletely absorbed. Because of this, Alka-ur may exert a mild laxative effect. Prolonged and excessive use may cause a systemic alkalosis and/or hypematraemia.


.


.


.


.


Sodium Saccharine


None 


24 Months

Store below 25C. Protect from moisture.


Sachet of 4.0 gm powder are packed in a carton
30 sachets in a carton
The primary packaging material is Trilaminate sachet foil
 


.


National Pharmaceutical Industries Co. (SAOG) P.O Box 120, Road No.15 Postal Code 124 Rusayl, Sultanate of Oman

.
}

صورة المنتج على الرف

الصورة الاساسية